Matches in DBpedia 2014 for { <http://dbpedia.org/resource/Catabasis_Pharmaceuticals> ?p ?o. }
Showing items 1 to 34 of
34
with 100 items per page.
- Catabasis_Pharmaceuticals abstract "Catabasis Pharmaceuticals, founded in 2008 and based in Cambridge, Mass., is a clinical-stage biopharmaceutical company developing bi-functional small molecules for treatment of dyslipidemias and inflammatory diseases. The company’s drug development programs are based on the principles of pathway pharmacology to treat diseases by modulating more than one target in a disease pathway simultaneously. Catabasis uses a proprietary linker technology to conjugate two drugs that act on different nodes of a disease pathway, with the intent of improving safety and efficacy of the two components. The conjugate is designed to keep the linked components inactive in plasma until they are cleaved by a specific class of intracellular enzymes, releasing both bioactives within the cells of target tissues.Catabasis has two programs in clinical development. CAT-2003, a conjugate of the B vitamin niacin and the omega-3 fatty acid eicosapentaenoic acid (EPA), is designed to treat severe hypertriglyceridemia and other lipid disorders and is currently in clinical testing. CAT-1004, a conjugate of the omega-3 fatty acid docosahexaenoic acid (DHA) and salicylate, has completed Phase 1 testing; the drug is being developed for the treatment of inflammatory diseases such as inflammatory bowel disease and Duchenne muscular dystrophy. In the Phase 1 study, results showed that CAT-1004 was safe and well tolerated,and that the linker technology allowed the active components to inhibit the NF-kB pathway synergistically;, this pathway plays an important role in inflammation.".
- Catabasis_Pharmaceuticals industry Pharmaceutical_drug.
- Catabasis_Pharmaceuticals location Cambridge,_Massachusetts.
- Catabasis_Pharmaceuticals numberOfEmployees "26".
- Catabasis_Pharmaceuticals type Privately_held_company.
- Catabasis_Pharmaceuticals wikiPageExternalLink www.catabasis.com.
- Catabasis_Pharmaceuticals wikiPageID "39607222".
- Catabasis_Pharmaceuticals wikiPageRevisionID "601867970".
- Catabasis_Pharmaceuticals homepage www.catabasis.com.
- Catabasis_Pharmaceuticals industry Pharmaceutical_drug.
- Catabasis_Pharmaceuticals keyPeople "Jill C. Milne, Ph.D. Michael Jirousek, Ph.D. Chris Thomajan Joanne M. Donovan, M.D., Ph.D. Michael Curtis, Ph.D. Henry Rath, M.B.A.".
- Catabasis_Pharmaceuticals location Cambridge,_Massachusetts.
- Catabasis_Pharmaceuticals logo File:Catabasis_logo_TM.png.
- Catabasis_Pharmaceuticals name "Catabasis Pharmaceuticals".
- Catabasis_Pharmaceuticals numEmployees "26".
- Catabasis_Pharmaceuticals products "Orally-delivered pharmaceuticals".
- Catabasis_Pharmaceuticals type Privately_held_company.
- Catabasis_Pharmaceuticals subject Category:Biopharmaceuticals.
- Catabasis_Pharmaceuticals type Agent.
- Catabasis_Pharmaceuticals type Company.
- Catabasis_Pharmaceuticals type Organisation.
- Catabasis_Pharmaceuticals type Organization.
- Catabasis_Pharmaceuticals type Agent.
- Catabasis_Pharmaceuticals type SocialPerson.
- Catabasis_Pharmaceuticals type Thing.
- Catabasis_Pharmaceuticals comment "Catabasis Pharmaceuticals, founded in 2008 and based in Cambridge, Mass., is a clinical-stage biopharmaceutical company developing bi-functional small molecules for treatment of dyslipidemias and inflammatory diseases. The company’s drug development programs are based on the principles of pathway pharmacology to treat diseases by modulating more than one target in a disease pathway simultaneously.".
- Catabasis_Pharmaceuticals label "Catabasis Pharmaceuticals".
- Catabasis_Pharmaceuticals sameAs m.0vxdjb_.
- Catabasis_Pharmaceuticals sameAs Q17143508.
- Catabasis_Pharmaceuticals sameAs Q17143508.
- Catabasis_Pharmaceuticals wasDerivedFrom Catabasis_Pharmaceuticals?oldid=601867970.
- Catabasis_Pharmaceuticals homepage www.catabasis.com.
- Catabasis_Pharmaceuticals isPrimaryTopicOf Catabasis_Pharmaceuticals.
- Catabasis_Pharmaceuticals name "Catabasis Pharmaceuticals".